Shots: In the P-I study, the companies will evaluate the OBDS with Ionis’ drug for in vitro compatibility and performance as well as in vivo safety, tolerability, and performance in a preclinical canine model Progenity expects that the alliance could demonstrate the versatility of OBDS in delivering a range of different molecules Ionis’ novel antisense […]Read More
Shots: The P-IIb study will evaluate three dose levels of ION449 (once a month, SC) vs PBO and will enroll ~108 patients aged 18-75yrs., who have LDL-C levels b/w 70-190 mg/dL and are receiving moderate/ high-intensity statin therapy The P-I study results demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90% […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
